Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
37
Participants
Timeline
Start Date
June 30, 2004
Primary Completion Date
June 30, 2007
Conditions
Lung Cancer
Interventions
DRUG
docetaxel
DRUG
thalidomide
Trial Locations (1)
22908
University of Virginia Cancer Center, Charlottesville
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
University of Virginia
OTHER
NCT00114192 - Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter